Self-reported Fatigue Predictive of Overall Survival in Myelodysplastic Syndromes

Share this content:
Self-reported fatigue assessment should be included in routine diagnostic investigation for higher-risk myelodysplastic syndromes.
Self-reported fatigue assessment should be included in routine diagnostic investigation for higher-risk myelodysplastic syndromes.

Self-reported fatigue assessment should be included in routine diagnostic investigation for patients with newly diagnosed higher-risk myelodysplastic syndromes and should be considered as a standard baseline stratification factor in future randomized controlled trials, according to an article published online ahead of print in JAMA Oncology.1

In this multicenter, observational, cohort study investigators sought to assess whether self-reported fatigue severity predicted overall survival better than gold-standard prognostic indices in patients with higher-risk myelodysplastic syndromes.

Adults with an intermediate-2-risk or high-risk International Prognostic Scoring System (IPSS) score were enrolled regardless of older age, comorbidities, and progression from a lower IPSS risk score category. All patients completed a quality of life assessment at baseline. A multivariate model of how prognostic variables predicted survival.

A total of 280 patients were enrolled between November 10, 2008 and August 13, 2012. With a median follow-up of 15 months, the median overall survival from diagnosis was 17 months (95% CI: 15–19.

In multivariate analysis, baseline factors independently associated with reduced overall survival were high-risk IPSS score (hazard ratio [HR] 2.525; 95% CI: 1.357–4-697; P=0·0035) and a higher score for fatigue (1.110; 1.040–1.170, for every ten points of fatigue deterioration; P=0.0007).

RELATED: Financial Toxicity Common in Patients With Multiple Myeloma

In further multivariate models for survival, including either the WHO-based prognostic scoring system or the revised version of the IPSS classification, self-reported fatigue was a statistically significant independent prognostic factor with a HR of 1.120 (1.050–1.180; P=0.0003) and a HR of 1.130 (1.060–1.190; P=0·0002), respectively. 

Reference

  1. Efficace F, Gaidano G, Breccia M, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. [published online ahead of print September 21, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00206-5. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters